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Abstract: Tumor necrosis factor α (TNF-α) influences endothelial cell viability by altering 
the regulatory molecules involved in induction or suppression of apoptosis. However, the 
underlying mechanisms are still not completely understood. In this study, we demonstrated 
that A20 (also known as TNFAIP3, tumor necrosis factor α-induced protein 3, and an  
anti-apoptotic protein) regulates the inhibitor of apoptosis protein-2 (cIAP-2) expression 
upon TNF-α induction in endothelial cells. Inhibition of A20 expression by its siRNA 
resulted in attenuating expression of TNF-α-induced cIAP-2, yet not cIAP-1 or XIAP.  
A20-induced cIAP-2 expression can be blocked by the inhibition of phosphatidyl inositol-3 
kinase (PI3-K), but not nuclear factor (NF)-κB, while concomitantly increasing the number 
of endothelial apoptotic cells and caspase 3 activation. Moreover, TNF-α-mediated 
induction of apoptosis was enhanced by A20 inhibition, which could be rescued by cIAP-2. 
Taken together, these results identify A20 as a cytoprotective factor involved in cIAP-2 
inhibitory pathway of TNF-α-induced apoptosis. This is consistent with the idea that 
endothelial cell viability is dependent on interactions between inducers and suppressors of 
apoptosis, susceptible to modulation by TNF-α. 
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1. Introduction 
Endothelial apoptosis has been implicated in the pathogenesis of diverse cardiovascular diseases, 
such as arteriosclerosis, ischemia-reperfusion disorders, and congestive heart failure [1]. The vascular 
endothelium is one of the major targets of tumor necrosis factor α (TNF-α) activity, which activates 
both cell survival and cell death mechanisms simultaneously. Several TNF-α-induced proteins 
including the Bcl-2 family [2], A1 and A20 [3,4], as well as inhibitors of apoptosis proteins (IAPs) [5] 
have been identified as having a role in the resistance against TNF-α-initiated apoptosis in endothelial 
cells. However, it is still not completely understood how these anti-apoptotic proteins are induced and 
shift the balance towards a TNF-mediated survival pathway. 
The IAPs are critical regulators of cell death and inflammation [6,7]. TNF receptor signaling 
complexes contain these anti-apoptotic molecules including X-linked inhibitor of apoptosis protein 
(XIAP), cellular inhibitor of apoptosis protein-1 (cIAP-1) and cellular inhibitor of apoptosis protein-2 
(cIAP-2), which are characterized by the presence of three N-terminal baculovirus IAP repeat (BIR) 
domains and a C-terminal RING domain that confers E3 ubiquitin ligase activity [8,9]. IAPs exert their 
anti-apoptotic effect through the inhibition of caspases [10]. However, IAPs also influence a multitude 
of other cellular processes, such as ubiquitin (Ub)-dependent signaling that regulates nuclear factor-κB 
(NF-κB) transcription factors activation, which in turn drives the expression of genes which is important 
for inflammation and cell survival [11,12]. In addition, other signaling pathways, including phosphatidyl 
inositol-3 kinase (PI3-K), have the potential to concurrently mediate cIAP-2 upregulation [13,14]. 
A20, (also called TNFAIP3, tumor necrosis factor α-induced protein 3), is an 80 kDa zinc finger 
protein consisting of seven Cys2/Cys2 zinc fingers [15], that binds to TRAF2 and is involved in the 
TNF-induced activation of NF-κB and AP-1 [16,17]. Rapid induction of the A20 gene upon TNF 
stimulation is suggested to involve the constitutive association of co-activators, such as CBP and p300, 
on the A20 promoter, mediated by the transcription factor Sp-1 [18,19]. Additionally, A20 possesses a 
dual ubiquitin editing function and regulates the NF-κB signaling pathway [20–22]. Besides TNF-α, 
A20 can also protect endothelial cells from Fas, TRAIL and high glucose-induced apoptosis [23–27]. 
A20 plays an important role in the degradation of the endocytic microbial product, staphylococcal 
enterotoxin B (SEB), in cardiac endothelial cells [24,28] and protect endothelial cells from  
natural killer (NK)-mediated cell death. Interestingly, mice deficient for A20 die prematurely due to 
severe inflammation and cachexia and are hypersensitive to TNF [29]. Subsequent analysis has 
revealed that not only does A20 inhibits cell proliferation, but it has also been linked to the increased 
angiogenesis [30,31]. Furthermore, A20 expression in human tumors has been suggested to be linked 
to the enhanced tumorigenesis via resistance to apoptosis [32].  
The precise mechanism by which either A20 or IAPs protects cells from apoptosis is not fully 
understood. Therefore, we analyzed the anti-apoptotic effect of A20 on the endothelium. We studied 
the effect of A20 on TNF-triggered apoptotic pathways. We have identified A20 as an important 
mediator in the role of cIAP-2, yet not cIAP-1, in TNF-α-induced endothelial apoptosis. Furthermore, 
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our data indicates that A20 protects endothelial cells from TNF-mediated apoptosis by signaling 
through a PI3-K signaling pathway and inhibiting proteolytic cleavage of the effector caspase 3. 
2. Results and Discussion 
2.1. Expression of A20 Is Regulated by Tumor Necrosis Factor α (TNF-α) 
Endothelial cells were exposed to TNF-α (20 ng/mL) stimulation for 4 h and examined by 
quantitative polymerase chain reaction (qPCR). Increased A20 mRNA levels were observed (Figure 1A). 
TNF-α-induced A20 upregulation in BAEC cells was also verified at the protein level by 
immunoblotting (Figure 1B). Furthermore, human embryonic kidney 293 (HEK293) cells were 
transiently transfected with a construct containing a sequence of the A20 promoter fragment and 
analyzed for luciferase activity. A20 promoter activity was markedly increased in response to TNF-α 
stimulation (Figure 1C), demonstrating that TNF-α mediated stimulation of A20 gene expression at the 
transcriptional level.  
Figure 1. A20 expression is upregulated by tumor necrosis factor α (TNF-α) in endothelial 
cells. (A) Quantitative PCR analysis of A20 mRNA expression in both human aortic 
endothelial cells (HAECs) and bovine aortic endothelial cells (BAECs) stimulated with TNF-α 
(20 ng/mL) for 4 h. The data is presented from triplet tests as means ± SD. * p < 0.05;  
(B) Expression of A20 was evaluated by immunoblot analysis in BAEC cells before and 
after 20 ng/mL TNF-α treatment for 4 h. Data shown is a representative blot of three 
experiments performed; and (C) The effect of TNF-α stimulation on A20 promoter activity 
was examined by luciferase activity assay in HEK 293 cells. Analysis was performed after 
4 h treatment of different doses of TNF-α. Results are expressed as luciferase activity from 
triplicate tests, and are presented as means ± SD. Statistical significance was determined as 
* p < 0.05 compared with control. 
 
2.2. A20 Induces the Expression of Cellular Inhibitor of Apoptosis Protein (cIAP)-2 but not cIAP-1 
To elucidate the role of A20 in TNF-α-related apoptotic pathways, A20 cDNA carried by a 
retrovirus was generated in endothelial cells. A20 proteins were successfully expressed in HAEC and 
BAEC cells. qPCR analysis demonstrated that cIAP-2 expression was increased by approximately  
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2.2-fold in A20 over expression (o/e) endothelial cells, however, neither cIAP-1 nor XIAP was 
significantly altered in BAEC cells infected with A20 retrovirus (Figure 2A). This was confirmed by 
immunoblot analysis (Figure 2B). Using two different sequences of A20 siRNA to knockdown A20 
expression in BAEC cells, both cIAP-2 mRNA and protein levels were significantly decreased; further 
corroborated that A20 induces cIAP-2 expression (Figure 2C). In addition, A20 considerably increased 
luciferase activity of the cIAP-2 promoter (Figure 2D) indicating that A20 induces expression of  
cIAP-2 at the transcriptional level.  
Figure 2. A20 induces the expression of cellular inhibitor of apoptosis protein (cIAP)-2 but 
not cIAP-1. (A) Quantitative PCR analysis for cIAP-2 mRNA expression was performed in 
BAEC cells. The data is presented from triplicate tests as means ± SD. * p < 0.05;  
(B) Immunoblot analysis comparing cIAP-2, cIAP-1 and XIAP in control and A20 
overexpressing BAEC and HAEC cells. Data shown is a representative blot of three 
experiments performed (left) and the related statistical graph (right). * p < 0.05;  
(C) Quantitative PCR analysis for cIAP-2 mRNA levels (left) and immunoblot analysis for 
cIAP-2 protein expression (right) was performed in BAEC cells, after knocking down A20 
expression by two different siRNA sequences targeted to A20. The data is presented from 
triplicate tests as means ± SD. * p < 0.05; and (D) Effect of A20 on cIAP-2 promoter 
activity was measured by luciferase assay in HEK293 cells transfected with A20 or control 
plasmids. The data is presented from triplicate tests as means ± SD. Statistical significance 
was determined as * p < 0.05 compared with control. 
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2.3. A20 Is a Mediator in TNF-α-Induced cIAP-2  
Among numerous cytokines and growth factors including VEGF, FGF2, IGF-1, TNF-α, IL-1β and 
PDGF that were incubated to BAECs, cIAP-2 mRNA levels were induced highest by TNF-α 
specifically (Figure 3A). TNF-α-induced cIAP-2 expression was demonstrated as a dose- and  
time-dependent manner (Figure 3B). Additionally, cIAP-2 mRNA levels were increased significantly 
at 3 h upon 10 ng/mL of TNF-α-stimulation and were sustained through 24 h. The level of cIAP-2 
gene expression increased significantly and reached a plateau at a dose between 10–50 ng/mL as 
verified by northern blotting (Figure 3B). The increase of cIAP-2 mRNA by TNF-α in BAECs was 
also confirmed in HAECs by qPCR (Figure 3C), while cIAP-1 and XIAP mRNA levels showed no 
significant difference (Figure 3D). Furthermore, the luciferase reporter demonstrated TNF-α induction 
of cIAP-2, but not cIAP-1 promoter activity (Figure 3E), suggesting that TNF-α regulated cIAP-2 at 
the transcriptional level. To further examine whether A20 was involved in TNF-α-induced cIAP-2 
expression, A20 expression was knocked down by A20 siRNA in HAECs. Figure 3F demonstrated 
that knockdown of A20 expression blocked TNF-α-induced cIAP-2 expression in both mRNA and 
protein levels. There was no significant difference in the expression of cIAP-1 and XIAP. Taken 
together, A20 may play an important role as an essential mediator involved in TNF-α-induced  
cIAP-2 expression.  
2.4. The PI3-K Signaling Pathway Is Involved in A20-Mediated TNF-α-Induced cIAP-2 Expression  
To determine the signaling pathway that is involved in A20-mediated cIAP-2 upregulation, 
endothelial cells were pre-treated with MAPK (ERK1/2, p38 and JNK) inhibitors and a PI3-K inhibitor 
prior to stimulation by TNF-α. cIAP-2 mRNA levels were inhibited upon treatment with the PI3-K 
inhibitor, yet not with the other MAPK inhibitors (Figure 4A). To determine whether NF-κB or  
PI3-kinase signaling is downstream during TNF-α-stimulated A20 and cIAP-2 expression, HAEC cells 
or A20 o/e HEMC cells were pre-treated with inhibitors of PI3-K and NF-κB. We observed  
that the PI3-K inhibitor substantially inhibited A20 levels as well as decreased cIAP-2 expression in  
A20 o/e HAEC cells (Figure 4B). Interestingly, both A20 and cIAP-2 expression were unaffected by 
the NF-κB inhibitor. TNF-α pre-treatment of HAEC cells significantly increased A20 and cIAP-2 
levels were, however, upon addition of the PI3-K inhibitor blocked the TNF-α upregulation of A20 
and cIAP-2 (Figure 4C). These data demonstrate that TNF-α-induced cIAP-2 expression may be 
partially mediated by A20 through the PI3-K signaling pathway.  
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Figure 3. cIAP-2 is upregulated by TNF-α-induced A20. (A) Northern blot analysis of 
cIAP-2 mRNA levels after stimulation with TNF-α (20 ng/mL), FGF2 (25 ng/mL), VEGF 
(25 ng/mL), IGF-1 (50 ng/mL), PDGF-AA (20 ng/mL), PDGF-BB (20 ng/mL), PDGF-AB 
(20 ng/mL), HGF (20 ng/mL) and IL1-β (5 ng/mL) in BAECs; (B) Northern blot  
showed TNF-α-induced cIAP-2 mRNA expression demonstrated as a dose-(upper) and  
time-(lower) dependent manner; (C) Quantitative-PCR analysis of cIAP-2 mRNA after 
stimulation with TNF-α (20 ng/mL), VEGF (25 ng/mL), IGF-1 (50 ng/mL) and IL1-β  
(5 ng/mL) for 4 h in HAECs. Results are expressed as fold change of control from triplicate 
tests, and are presented as means ± SD. * p < 0.05; (D) Quantitative-PCR analysis of cIAP-1, 
cIAP-2 and XIAP mRNA levels after stimulation with TNF-α (20 ng/mL) for 4 h in 
HAECs. Results are expressed as fold changes of control from triplicate tests, and are 
presented as means ± SD. * p < 0.05; (E) Effect of TNF-α stimulation on cIAP-2 and 
cIAP-1 promoter activity by luciferase activity assay. Results are expressed as fold change 
to control from triplicate tests, and are presented as means ± SD. * p < 0.05; and  
(F) Targeted knockdown of A20 expression by A20 siRNAs after TNF-α (20 ng/mL) 
stimulation of cIAP-2 protein expression analyzed by immunoblot (left) and mRNA levels 
by quantitative PCR (right). Results are expressed as fold change to control from triplicate 
tests, and are presented as means ± SD. * p < 0.05. 
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Figure 3. Cont. 
 
Figure 4. The PI3-K signaling pathway is involved in A20-mediated TNF-α-induced 
cIAP-2 expression. (A) Quantitative-PCR analysis of cIAP-2 mRNA levels in HAECs  
pre-treated with LY294002 (25 μM, PI3-K inhibitor), U0126 (10 μM, ERK1/2 inhibitor), 
SB203580 (20 μM, p38 inhibitor), and SP600125 (20 μM, JNK inhibitor), respectively for 
1 h. Results are expressed as fold change to control from triplicate tests, and are presented 
as means ± SD. * p < 0.05; (B) Immunoblot analysis in A20 o/e HAECs pre-treated with 
either wedelolactone (20 μM, IKKα/β inhibitor) or LY294002 (25 μM, PI3-K inhibitor) for 
1 h and then immunoblotted for A20, cIAP-2 and vinculin. Representative blot is shown; 
and (C) Immunoblot analysis in HAECs stimulated with TNF-α (20 ng/mL) and together 
with either (20 μM, IKKα/β inhibitor) or LY294002 (25 μM, PI3-K inhibitor). A20, cIAP-1 
and β-actin were blotted. Representative blot is shown. 
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2.5. A20-Mediated cIAP-2 Is Important in Endothelial Cell Resistance to TNF-α-Induced Apoptosis  
To assess the endothelial apoptotic effect of A20 in TNF-α-induced cIAP-2 expression, caspase-3 
activity was measured in BAEC cells after TNF-α-stimulation. The caspase-3 activity increased by  
4-fold upon stimulation with TNF-α as compared to controls (Figure 5A). Importantly, when either 
cIAP-2 or A20 was knocked down using siRNAs, TNF-α-induced caspase-3 activation was increased 
in comparison with control siRNA (Figure 5B), indicating an A20-mediated inhibitory effect of  
cIAP-2 on caspase-3 activity induced by TNF-α. Using PO-PRO-1 dye and 7-AAD staining to identify 
the consequences of TNF-α-induced apoptosis in endothelial cells, the results indicated that the 
addition of A20 decreased the number of apoptotic cells that were induced by TNF-α (29.2 ± 1.8 vs. 
36.1 ± 1.9), so did cIAP-2 (30.0 ± 1.9 vs. 36.1 ± 1.9) (Figure 5C). Moreover, there was a similar 
increase in TNF-α-induced apoptotic cells when we knocked down expression of either A20 (50.7 ± 1.4 
vs. 37.9 ± 1.3) or cIAP-2 (48.3 ± 5.2 vs. 37.9 ± 1.3) by their siRNA (Figure 5D). However, when cIAP-2 
was knocked down, a decrease in apoptotic cells by additional A20 was observed (48.3 ± 5.2 vs.  
36.1 ± 1.1). A20 siRNA increased the TNF-α-induced apoptotic cells could be rescued by additional 
cIAP-2 (50.7 ± 1.4 vs. 39.1 ± 1.5), suggesting an inhibitory effect of A20 in apoptosis is, at least in part, 
through induction of cIAP-2 (Figure 5D).  
2.6. Discussion 
Endothelial apoptosis results in vascular leakage, as well as the activation of inflammation and 
coagulation pathways, and has been suggested to be an important mechanism of many diseases [1].  
We aimed to determine the mechanisms that prevent endothelial cells from apoptotic damage, despite 
being in continuous touch with hostile environments. Recent evidence indicates that IAPs are 
frequently expressed in cancer, and their uncontrolled over-expression has been implicated in 
contributing to tumorigenesis, chemoresistance, disease progression and poor patient survival [33].  
In this study, we extend these findings by also showing that cIAP-2 induction is critical for the 
resistance of endothelial cells to TNF-α-induced apoptosis. TNF-α stimulates cIAP-2 expression via 
induction of A20, a protective gene in endothelial cells. Additionally, A20 plays an important role in 
mediating this TNF-α-induced cIAP-2 expression. Our data also demonstrate that TNF-α-induced 
cIAP-2 and A20 significantly prevented endothelial cells from undergoing TNF-α-induced apoptosis.  
A20 was initially identified as a primary response gene following stimulation of human umbilical 
vein endothelial cells (HUVEC) with TNF-α, IL-1 or LPS [32–34]. Based on references, TNF-α may 
induce endothelial cells elongation [35] and A20 may inhibit the elongation of endothelial cells [18]. 
To observe whether A20 has impact on the TNF-α induced elongation of endothelial cells, we have 
checked the cell morphology induced by A20 previously, but no obvious changes were found (data not 
shown). Furthermore, the relationship between A20 and other anti-apoptotic genes, especially IAPs, 
which also prevent endothelial cells from TNF-α-induced apoptosis, has not been well-investigated.  
In the current study, we observed that A20 induced the expression of cIAP-2 but not that of cIAP-1 
and XIAP. We also demonstrated that A20 knockdown reduced TNF-α-induced expression of cIAP-2 
and effect TNF-α-induced apoptosis, suggesting that A20 is the mediator in TNF-α-induced cIAP-2. 
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Our present study demonstrates that TNF-α induces A20-mediated cIAP-2 expression through a 
PI3-K-specific pathway, yet not through NF-κB, as demonstrated by the inability of an IKK inhibitor, 
wedelolactone, to block A20-induced cIAP2 expression. While A20 has been reportedly involved in a 
negative feedback loop to block NF-κB activation in response to TNF-α [29,36] and TNF-α-induced 
IAPs through the NF-κB signaling pathway [5,37], our evidence implicating A20-induced cIAP-2 
expression is NF-κB-independent seems controversial. However, in contrast to its inhibitory effect on 
NF-κB activation, the anti-apoptotic activity of A20 remains unclear and appears to be specific to cell 
type and stimulus [24,38–41] and possibly dependent on its recently characterized ubiquitin editing 
function [22,42]. Additionally, more recent reports indicated that TNF-α-induced IAPs through an  
NF-κB-independent pathway [43]. cIAP-2 involvement in NF-κB signaling has also been questioned, 
as studies in cIAP-2 null mice have not supported such a role [44,45]. Our data suggests that treatment 
with wedelolactone did not affect cIAP-2 protein levels in A20 overexpressing cells, suggests that the 
A20 increasing of cIAP-2 is NF-κB-independent. Our results are consistent with previous findings 
demonstrating an involvement of the PI3-K pathway in regulating IAP gene expression [13,14] and 
provide additional information that A20 directly regulates the gene level of cIAP-2 via PI3-K. 
Interestingly, VEGF is also considered as a potent PI3-K activator, but VEGF does not result in cIAP2 
upregulation in our study which we confirmed by three experiments. This alternative reaction may be 
involved in other factors in this pathway, which should be proved by our future study. In the present 
study, we confirmed that TNF-α activated three of the main MAPK family pathways in endothelial 
cells; however, the ERK, JNK and p38 pathways did not appear to be involved in TNF-α-induced 
cIAP-2 expression. Several articles have reported both cIAP-2 and A20 are involved in the similar 
pathways of anti-apoptosis. It was reported that the binding of cIAP-1 to A20, in which the baculovirus 
IAP repeat 2 (BIR2) and BIR3 domains together are required and sufficient [46]. Considering both 
BIR2 and BIR3 domains are also in cIAP-2 sequence, it is possible there is the interaction of A20 and 
cIAP-2. However, other report indicated that cIAP2-Malt1 fusion was recognized by A20 through the 
Malt1 terminal instead of cIAP-2 terminal [47]. Therefore, whether there is a direct interaction 
between A20 and cIAP-2 still need to be further proved. 
Caspase activation is central to the regulation of many apoptotic pathways. Studies of caspase 
activation in diseases have revealed intricate mechanisms regulating cell survival and death. It is also 
well known that IAPs exert their anti-apoptotic effect through the inhibition of caspases [10,48]. 
Previous studies also indicated that TNF-α can activate the caspase-3-mediated pathway [49], and our 
results are also consistent with these earlier studies. Understanding the TNF-α-triggered anti-apoptotic 
response could shed light for future investigations into the therapeutic utility of TNF antagonists in 
preserving endothelial function and integrity in cardiovascular disorders. Although studies in 
experimental models and preliminary clinical studies suggested a possible therapeutic role for the 
soluble TNF antagonist [50,51], the results of large multiple-center trials failed to show a clinically 
relevant benefit of targeted anti-cytokine therapy with the soluble TNF antagonist, Etanercept, on the 
rate of death or hospitalization in heart failure [52]. Meanwhile, both increased and decreased risks of 
heart failure among patients with rheumatoid arthritis starting a TNF antagonist were reported [53–56]. 
These confusing findings suggest that there is a need to explore other mediators that may play 
instrumental roles in the intricate anti-apoptotic pathway. The present results that TNF-α strongly 
induces A20-mediated cIAP-2 expression through the PI3-K pathway, and that A20 as well as cIAP-2 
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knockdown sensitizes endothelial cells to apoptosis, provides complementary information to the  
TNF-α downstream signaling pathways. This study indicates that the regulation of A20 and other  
anti-apoptotic genes could be involved in the therapeutic strategies against TNF-α signaling in cancer 
or cardiovascular disease.  
Figure 5. A20-mediated cIAP-2 is important in endothelial cell resistance to  
TNF-α-induced apoptosis (caspase3 activity). (A) Caspase-3 activity was analyzed in the 
BAEC cell lysates treated with various concentrations of TNF-α by means of a colorimetric 
assay calculated as pmol p-nitroaniline released per min per μg cellular protein. 
Colorimetric readings were performed in a plate reader at an optical density of 405 nm. 
The data is presented as percentage of control from triplicate tests as means ± SD.  
* p < 0.05; (B) Caspase-3 activity was analyzed in TNF-α-stimulated BAEC cells 
transfected with siRNAs targeted to cIAP-2 and A20 siRNA to knockdown expression. 
The data is presented as percentage of control from triplicate tests as means ± SD.  
* p < 0.05; (C) Flow cytometry analysis of endothelial cells stained with PO-PRO-1 dye 
and 7-AAD to examine the effect of A20 and cIAP-2 overexpression (induced by 
transfection) on TNF-α-induced apoptotic cells. Representative flow cytometry plots (left) 
and statistic graph (means ± SD) (right) were shown. * p < 0.05, vs. control cells; # p < 0.05, 
vs. TNF-α-stimulated control cells; and (D) Flow cytometry analysis of endothelial cells 
stained with PO-PRO-1 dye and 7-AAD to examine the effect of knockdown of either A20 
or cIAP-2 by siRNAs on TNF-α-induced apoptotic cells, or transfection with siRNAs 
targeted to A20 or cIAP-2 and/or plasmids containing full length cDNA of cIAP-2 or A20 
respectively to determine if TNF-α-induced apoptotis could be rescued. Representative 
flow cytometry plots (left) and statistic graph (means ± SD) (right) were shown. * p < 0.05, 
vs. control siRNA group; ‡ p < 0.05, vs. control siRNA+ TNF-α group; # p < 0.05, vs. 
cIAP-2 siRNA+ TNF-α group; † p < 0.05, vs. A20 siRNA+ TNF-α group. 
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3. Experimental Section  
3.1. Cell Culture and Inhibitor Treatment 
Bovine aortic endothelial cells (BAECs) were purchased from Lonza (Walkersville, MD, USA), 
and cultured in Dulbecco’s Modified Eagle’s Medium (Invitrogen, Carlsbad, CA, USA) with 10% fetal 
bovine serum (FBS) (Invitrogen). Human aortic endothelial cells (HAECs) (Lonza), were cultured in 
endothelial basal medium2 (EBM2) (Lonza) containing 2% FBS with growth supplements. The cells 
were passed every 4–5 days, and experiments were performed on either third or fourth passage of cells. 
After cells had grown to confluence, they were placed in a starvation medium (0.5% FBS) for 16 h. 
Starved cells were pretreated for 1 h with vehicle or selective 25 μM PI3-K inhibitor LY294002 
(Sigma, St. Louis, MO, USA), 10 μM MEK inhibitor U0126 (Calbiochem, Billerica, MA, USA),  
20 μM selective p38 MAP kinase inhibitor SB203580 (Alexis, San Diego, CA, USA), 20 μM selective 
JNK inhibitor SP600125 (Alexis) or 20 μM IKK α/β inhibitor Wedelolactone (Calbiochem), followed 
by treatment with 20 ng/mL TNF-α (Sigma). The concentration of inhibitors was in accordance with 
doses used in the previous studies [57–59]. 
3.2. Growth Factor Stimulation Studies  
Selective growth factors and cytokines, including TNF-α (20 ng/mL), FGF2 (25 ng/mL, Chiron, 
Emeryville, CA, USA), VEGF (25 ng/mL, Genetech, Plano, TX, USA), IGF-1 (50 ng/mL, Sigma), 
PDGF-AA (20 ng/mL, Sigma), PDGF-BB (20 ng/mL, Sigma), PDGF-AB (20 ng/mL, Sigma), HGF  
(20 ng/mL, Sigma) and IL1-β (5 ng/mL, Sigma) , were added in BAECs or HAECs. The concentration 
of the growth factors was in accordance with doses used in a previous study [60]. After 4 h treatment, 
Northern blot analysis or Quantitative-PCR analysis was performed.  
  
Int. J. Mol. Sci. 2014, 15 3827 
 
 
3.3. Retroviral Construction 
Control vector or Flag-HA-A20 (Addgene, Cambridge, MA, USA) was transfected to HEK293T 
cells (American Type Culture Collection, Manassas, VA, USA) using polyethylenimine (PEI) with 
pVSV-G, pJK3, and pCMVtat. The medium containing retrovirus-A20 was collected 48 h post 
transfection and filtered before being used to infect HAECs and BAECs. The transfected gene 
expression was confirmed using western blot analysis.  
3.4. Western Blot Analysis 
Whole-cell lysates were obtained from cultured cells with RIPA buffer (Boston Bioproducts Inc., 
Ashland, MA, USA) containing protease inhibitor cocktail (Roche, Basel, Switzerland) plus 10 mM 
NaF and 10 mM Na3VO4. Proteins were fractionated by 10% SDS-polyacrylamide gel and transferred 
to PVDF membranes (Millipore, Billerica, MA, USA). Membranes were incubated with the following 
antibodies: Anti-A20 (Active Motif, Carlsbad, CA, USA); Anti-cIAP-1, Anti-cIAP-2, Anti-β-actin 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); Anti-GAPDH (Millipore); Anti-XIAP (Transduction 
Laboratories, San Jose, CA, USA); and Anti-vinculin (Sigma). Following incubation of anti-IgG,  
the proteins were visualized using an ECL detection system (Amersham, Piscataway, NJ, USA). 
3.5. Promoter Activity Analyses 
A fragment of human cIAP-2 promoter (−1066 to +38, GeneBank NM_001165) and cIAP-1 
promoter (−1083 to +79, GeneBank NM_001166) was cloned into a PGL-3 vector (Promega,  
San Luis Obispo, CA, USA) containing the luciferase reporter. The A20 luciferase construct was a gift 
from Dr. Kun-Sang Chang, from the University of Texas MD Anderson Cancer Center (Houston, TX, 
USA) HEK293T cells (ATCC, Washington, DC, USA) were transfected with the cIAP-1, cIAP-2 and 
A20 promoter constructors using PEI, Polyethyleneimine (Polysciences, Inc., Warrington, PA, USA).  
20 ng/mL of TNF-α was added, cells were lysed 4 h later, and the luciferase activity was determined 
with a dual-luciferase assay system (Promega). 
3.6. siRNA Transfection 
siRNAs targeting A20 (Shanghai GenePharma Co., Ltd., Shanghai, China), and cIAP-2  
(Qiagen, Valencia, CA, USA) were prepared. The siRNAs were transfected using Lipofectamine 2000 
(Invitrogen) according to manufacturer’s instructions into 30%–50% confluent HAECs or BAECs at a 
final concentration of 20 nM. Seventy-two hours after transfection, the efficacy of knockdown was 
assessed by Western blot assay and qPCR.  
The sequences of the siRNAs are as the Table 1. 
Table 1. The sequences of the siRNAs. 
No. A20 siRNA cIAP-2 siRNA 
1 5'-GAA GUG GAC UUC AGU ACA ATT-3' 5'-CCU CUA GUG UUC UAG UUA ATT-3'
2 5'-GCG GAA AGC UGU GAA GAU ATT-3' 5'-GCU CCU UCU UUA AGA AAG UTT-3'
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3.7. RNA Analysis 
Total RNA from BAECs and HAECs was extracted with TRIzol Reagent (Invitrogen), and cDNA 
was synthesized by reverse transcription. RNA levels were measured by quantitative polymerase chain 
reaction using the following six primers in Table 2. 
Table 2. The sequences of the qPCR primers. 
Gene names Human Bovine 
cIAP1 
(F) 5'-GTTTCAGGTCTGTCACTGGAAG-3' – 
(R) 5'-TGGCATACTACCA GATGACCA-3' – 
cIAP2 
(F) 5'-TCCTGGATAGTCTACTAACTGCC-3' 5'-TCAAATGCTTCTGTTGTGTAC-3' 
(R) 5'-GCTTCTTGCAGAGAGTTTCTGAA-3' 5'-CTGAATGTGTGTAATTCGT-3' 
XIAP 
(F) 5'-ACCGTGCGGTGCTTTAGTT-3' 5'-GTCATGCAGCAGTAGATAG-3' 
(R) 5'-TGCGTGGCACTATTTTCAAGAT-3' 5'-CATGAGTCTCAGATGGCCT-3' 
A20 
(F) 5'-AAGCTGTGAAGATACGGGAGA-3' – 
(R) 5'-CGATGAGGGCTTTGTGGATGAT-3' – 
GAPDH 
(F) 5'-TGGTGAAGCAGGCATCTGAG-3' – 
(R) 5'-CTCCTGCGACTTCAACAGCA-3' – 
RNA for Northern Blot analysis was fractionated on a 1.3% formaldehyde-agarose gel, transferred 
to nitrocellulose membrane, and hybridized at 68 °C for 3 h with a random-primed, 32P-labeled IAP-2 
cDNA probe in QuikHyb solution (Stratagene, La Jolla, CA, USA). The cIAP-2 probe was prepared by 
reverse transcription–polymerase chain reaction (PCR) with 5'-AGT CTT GCT CGT GCT GGT TT-3' 
and 5'-ATT CGA GCT GCA TGT GTC TG-3', corresponding to 433 to 1055 in human IAP-2  
cDNA sequence [14].  
3.8. Plasmid Transfection 
Control vector, Flag-HA-A20 or Flag-cIAP-2 was transfected into BAECs using Lipofectamine 
reagent (Invitrogen) to get transient overexpression. 
3.9. Apoptosis Assay  
Apoptotic cells were analyzed with the Vybrant Apoptosis Assay Kit 13 (BD Pharmingen,  
San Diego, CA, USA) for flow cytometry. The cells stained with PO-PRO-1-labeled annexin V and  
7-AAD were analyzed by flow cytometry on a FACScan using CellQuest software according to 
manufacturer’s instructions. Cells that were Annexin V positive and 7-AAD negative were counted for 
early stages of apoptosis to exclude necrotic cells. 
Caspase-3 cellular activity was measured by using a caspase-3 assay kit (Calbiochem) according to 
the manufacturer’s directions. Caspase-3 activity was assessed in endothelial cell extracts after TNF-α 
treatment for the time and concentration indicated in the figure. Caspase-3 activity was expressed as 
picomoles of p-nitroaniline released per minute per microgram of cellular protein. Colorimetric 
readings were performed in a plate reader at an optical density of 405 nm. 
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3.10. Statistics 
Results are expressed as mean ± SD on the basis of triplicate experiments. Statistical analysis used 
ANOVA and Student t test (2 tailed). A value of p < 0.05 was considered statistically significant. 
4. Conclusions  
In a word, these results identify A20 as a cytoprotective factor involved in cIAP-2 inhibitory pathway 
of TNF-α-induced apoptosis. This is consistent with the idea that endothelial cell viability is dependent 
on interactions between inducers and suppressors of apoptosis, susceptible to modulation by TNF-α. 
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